Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 6, 2026

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

View original at seekingalpha.com

Eli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

Retatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement
60% confidence
Discontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level
60% confidence
About one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range
60% confidence
In TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%
60% confidence
Up to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)
60% confidence
Retatrutide reduced knee osteoarthritis pain scores by as much as 73%
60% confidence
More than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity
60% confidence
In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks
60% confidence
GLP-1 drug market sales forecast raised to $150 billion
60% confidence
Among more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)
60% confidence
Highest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end
60% confidence
Retatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies
60% confidence